New to Meducation?
Sign up
Already signed up? Log In
view moderators

MacularDegeneration

Category

Preview
0
0

Delayed Visual Improvements in AMD Continue With Ranibizumab Treatment

Visual improvements in patients with neovascular age-related macular degeneration (AMD) treated with ranibizumab continue after macular edema resolves, researchers report.  
medscape.com
over 3 years ago
Preview
0
0

Dexamethasone Implant Helps Some With Diabetic Macular Edema

An intravitreal dexamethasone implant (Ozurdex, Allergan) can prompt improvement in patients with diabetic macular edema refractory to multiple anti-vascular endothelial growth factor (anti-VEGF) injections, according to Korean researchers.  
medscape.com
over 3 years ago
Preview
0
0

Modifiable Risk Factors for AMD: The Role of Statins

If cardiovascular disease and age-related macular degeneration (AMD) share some pathophysiologic mechanisms, would interventions that reduce cardiovascular disease help reduce the progression of AMD?  
medscape.com
over 3 years ago
Preview
0
0

Low Vitamin D Levels Linked to Macular Degeneration Risk

Adults with the lowest levels of circulating vitamin D levels had the highest risk for age-related macular degeneration, particularly late-stage, compared with those with the highest levels.  
medscape.com
over 3 years ago
Preview
0
0

AMD: Untreated Sleep Apnea May Reduce Response to Bevacizumab

A small, single-center study has suggested untreated sleep apnea reduces treatment response to bevacizumab in patients with exudative age-related macular degeneration.  
medscape.com
over 3 years ago
Preview
0
0

Many With Wet AMD Need Ranibizumab Retreatment Even After Year-Long Pause

Retreatment with ranibizumab is necessary for up to a third of neovascular age-related macular degeneration (AMD) patients who are treatment-free for one year, new research shows.  
medscape.com
over 3 years ago
Preview
0
0

Persistent Diabetic Macular Edema: Converting Eyes to Aflibercept

In patients with persistent diabetic macular edema, switching from an older VEGF inhibitor to a newer one may improve outcomes. Conversion to aflibercept may now be another option.  
medscape.com
over 3 years ago
Preview
0
8

Higher priced drugs are not cost effective for diabetic macular edema, US study finds

In comparsion with treatment with the low cost antivascular endothelial growth factor (VEGF) drug bevacizumab (Avastin), the more expensive alternatives aflibercept (Eylea) and ranibizumab (Lucentis) are not cost effective for diabetic macular edema, a new study has found.1  
feeds.bmj.com
over 3 years ago
Preview
0
10

Two Expensive Diabetic Macular Edema Drugs Not Cost-effective

Anti-VEGF medicines aflibercept and ranibizumab would have to drop in price by 69% and 80%, respectively, to be worth the societal cost compared with bevacizumab, a new study has found.  
medscape.com
over 3 years ago